EMA Withdrawn: Busilvex (busulfan) — Pierre Fabre Medicament

View source ↗

Summary

EMA withdrew Busilvex (busulfan) from the market; the product is no longer authorized in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematopoietic Stem Cell Transplantation

Drugs mentioned

• Busilvex (busulfan)

Snippet

Status: Withdrawn. Therapeutic area: Hematopoietic Stem Cell Transplantation. MAH: Pierre Fabre Medicament. Decision date: 01/02/2022